

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **EXTENSION OF TIME FOR DESPATCH OF CIRCULAR**

Reference is made to the announcement of WuXi Biologics (Cayman) Inc. (the “**Company**”) dated March 19, 2019 in relation to the Grant and appointment of independent financial advisor (the “**Announcement**”).

Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, further details of the issue and allotment of the Connected Restricted Shares and the Specific Mandate, a letter of advice from the Independent Board Committee to the Independent Shareholders, a letter of advice from Gram Capital to the Independent Board Committee and the Independent Shareholders in respect of the issue and allotment of Connected Restricted Shares to the Connected Grantees, other relevant resolutions to be considered at the 2019 AGM, and the notice convening the 2019 AGM, is expected to be despatched to the Shareholders on or before April 10, 2019.

As additional time is required for the Company to finalize certain information in the Circular, the despatch date of the Circular is expected to be extended to a date falling on or before April 29, 2019.

For and on behalf of  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, April 10, 2019

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.*

\* *For identification purpose only*